home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Pipeline: Portfolio Strategy Congress

 
  November 06, 2003  
     
 
Institute for International Research, Loew Hotel, Philadelphia, PA
3/31/2004 - 4/2/2004


IIR's Pipeline: Portfolio Strategy Congress is a 4-tracked large scale event with over 75 senior-level speakers, addressing key business strategy issues for the pharmaceutical and biotechnology industries. This event seeks program speaking and delegate participation of very senior level VP/Director level business development and licensing executives on leading strategies in licensing, strategic alliances, mergers and acquisitions, biotechnology financing, technology financing and intellectual property. The program sessions will focus on best practices and case studies on the use of creative new deal structures, success and failure stories of bio/pharma partnering, and how biotechnology companies are raising capital to stay alive if they are not getting the deals to fund their research. Several keynote addresses focus on the impact of consolidation in the industry, the future of R & D/technology spending, state of deal structures overall and more.
 
 
Organized by: Institute for International Research
Invited Speakers: Gary Cupit, VP Business Development and Licensing, NOVARTIS
Osagie Imasogie, VP and Director of Genetics and Discover Ventures, GLAXOSMITHKLINE
Subhanu Saxena, Global Head, Business Development and Licensing Primary Care, NOVARTIS
Richard Heaslip, PhD, Vice President, Project Planning and Administration, Project Management, WYETH RESEARCH
Allen D. Roses, MD, Senior Vice President, Genetics Research, GLAXOSMITHKLINE
Dean A. Slack, Director of Strategic Analysis, BAYER CORPORATION
Peter Benton, Vice President, Central Planning, JOHNSON AND JOHNSON
Anthony Watkins, Manager, Corporate Finance and Investment Banking, ELI LILLY AND COMPANY
Peter Bissinger, Managing Director, NOVARTIS BIOVENTURE FUND
Barbara Yanni, Chief Licensing Officer and Vice President, MERCK

And Many more

 
Deadline for Abstracts: hko@iirusa.com
 
Registration: www.rxbiopipeline.com or 888-670-8200
E-mail: hko@iirusa.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.